Lexicon Pharmaceuticals, Inc.
LXRX
$0.3918
$0.02416.55%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -28.28% | -18.98% | -51.55% | -63.17% | -116.04% |
| Total Depreciation and Amortization | -16.56% | -3.47% | 28.57% | 42.72% | 39.81% |
| Total Amortization of Deferred Charges | -34.95% | 92.31% | 95.09% | 79.13% | 184.79% |
| Total Other Non-Cash Items | 241.75% | -100.66% | 19.36% | -16.85% | -89.24% |
| Change in Net Operating Assets | 23.41% | 66.34% | -230.45% | -182.16% | 705.33% |
| Cash from Operations | -28.83% | -27.34% | -74.39% | -134.35% | -114.10% |
| Capital Expenditure | -269.88% | -79.86% | -- | 100.00% | -1,975.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 237.03% | 83.79% | -993.15% | 104.16% | 49.16% |
| Cash from Investing | 235.96% | 83.48% | -1,011.47% | 114.69% | 49.06% |
| Total Debt Issued | -- | -- | -- | -100.00% | 100.40% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | -- | -109.95% | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -336.19% | -100.01% | 29,151.33% | -100.00% | -100.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.69% | -179.82% | 463.89% | -95.10% | -3,002.26% |
